help button home button Am J Pathol ASIP MEMBERSHIP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, J.
Right arrow Articles by Zutter, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, J.
Right arrow Articles by Zutter, M. M.
(American Journal of Pathology. 2002;161:337-344.)
© 2002 American Society for Investigative Pathology


Animal Models

The {alpha}2 Integrin Subunit-Deficient Mouse

A Multifaceted Phenotype Including Defects of Branching Morphogenesis and Hemostasis

Jianchun Chen*, Thomas G. Diacovo{dagger}, David G. Grenache*, Samuel A. Santoro* and Mary M. Zutter*

From the Departments of Pathology and Immunology*and Pediatrics,{dagger}Washington University School of Medicine, St. Louis, Missouri

Abstract

The {alpha}2ß1 integrin is a collagen/laminin receptor expressed on platelets, endothelial cells, fibroblasts, and epithelial cells. To define the role of the {alpha}2ß1 integrin in vivo, we created a genetically engineered mouse in which expression of the {alpha}2ß1 integrin was completely eliminated. Mice deficient in the {alpha}2ß1 integrin are viable, fertile, and develop normally with no excess lethality of homozygotes. Both {alpha}2ß1-integrin protein and {alpha}2 mRNA were undetectable in the {alpha}2-null mice. Gross and histological evaluation of the heart, lungs, kidneys, gastrointestinal tract, pancreas, skin, and reproductive tracts revealed no abnormalities. However, quantitative analysis of mammary gland branching morphogenesis demonstrated that branching complexity is markedly diminished in the {alpha}2-deficient animals. Studies in the {alpha}2-deficient animals do not support the proposed roles for the {alpha}2ß1 integrin on fibroblasts and keratinocytes in wound healing. When compared to platelets from wild-type littermates, platelets from {alpha}2-null mice failed to adhere to type I collagen under either static or shear-stress conditions. Although platelets from {alpha}2-deficient animals aggregated in response to collagen, they did so with prolonged lag time and lessened intensity. The {alpha}2ß1 integrin-null mouse thus exhibits diverse, sometimes subtle, phenotypes consistent with the widespread pattern of {alpha}2ß1 integrin expression.


The {alpha}2ß1 integrin functions as a collagen receptor on platelets and fibroblasts and as both a collagen and laminin receptor on endothelial cells and epithelial cell types.1-3 The {alpha}2ß1 integrin has been implicated in a variety of complex biological processes. An abundant literature supports an important role for the {alpha}2ß1 integrin in platelet function and hemostasis.4 Extensive in vitro studies of renal, pulmonary, gastrointestinal, and breast epithelia suggested that signals downstream of {alpha}2ß1-integrin ligation contribute to branching morphogenesis.5-8 Experiments using explant cultures and three-dimensional collagen gels have implicated the {alpha}2ß1 integrin in keratinocyte migration and fibroblast contraction during wound healing.9-11

To define better the role of the {alpha}2ß1 integrin in vivo, we created a genetically engineered mouse in which expression of the {alpha}2ß1 integrin was eliminated. We now show that mice deficient in the {alpha}2ß1 integrin are viable and fertile. However, {alpha}2ß1-integrin-deficient mice show defective hemostasis and abnormalities of branching morphogenesis, but apparently normal healing of skin wounds.

Materials and Methods

The Targeting Construct

Screening of a P1 129/Svj DNA genomic library (Genomic Systems, St. Louis, MO) by polymerase chain reaction (PCR) using primers directed against bp -15 to +6 and 165 to 186 of exon 1 of the murine {alpha}2-subunit cDNA sequence12 yielded a 100-kb P1 clone. The targeting vector [loxP neo/TK vector (a gift from Dr. Robert Schreiber, Washington University, St. Louis, MO)] was prepared from an 8.0-kb EcoRI restriction enzyme fragment from the P1 genomic clone containing exon 1 (Figure 1A) . A 2.0-kb BamHI fragment consisting of 5' untranslated region of the {alpha}2 integrin gene was inserted upstream of the 5' loxP site. The contiguous 600-bp BamHI fragment containing exon 1 and flanking sequence was placed between the two downstream loxP sites. A 2.4-kb Aval/EcoRI fragment containing intronic sequence was placed between the 3' loxP site and the PGK-TK cassette, as shown in Figure 1A .



View larger version (31K):
[in this window]
[in a new window]
 
Figure 1. Targeting of the {alpha}2 integrin gene. A: The targeting construct was prepared from an 8.0-kb EcoRI genomic clone containing exon 1 (black box). The targeting vector contained a 2.0-kb BamHI fragment that included 5' UTR of the {alpha}2 integrin gene upstream of the 5' loxP (triangle) site. A 600-bp BamHI fragment containing exon 1 and flanking sequence was placed between the two downstream loxP sites. A 2.4-kb Aval/EcoRI fragment containing intronic sequence was placed between the 3' loxP site and the PGK-TK cassette. The fragment used for Southern blot hybridization (probe a), primers (1 and 2) for PCR genotyping, restriction enzyme sites, the 5' UTR, and intron 1 are indicated. After homologous recombination, transient transfection with a plasmid encoding Cre-recombinase resulted in removal of both the neo-cassette and exon 1. A single loxP site remained. Restriction enzyme sites: B, BamHI; A, Aval; R, EcoRI; X, Xho. B: Southern blot analysis of wild-type, heterozygous, and {alpha}2-deficient animals. Tail DNA from mice obtained from the heterozygous intercrosses was digested with EcoRI and Xhol, electrophoresed, and hybridized with probe a. The wild-type allele generates a 6.5-kb fragment and the targeted allele generates a 4.5-kb fragment. C: PCR genotyping of tail DNA. The genotype was confirmed by PCR analysis of tail DNA using primer 1, directed against the 5' UTR of the {alpha}2 integrin gene and primer 2 against intron 1. The wild-type allele generated an 870-bp product and the mutant allele generated a 320-bp product.

 
Generation of {alpha}2-Deficient Mice

R1 embryonic stem cells derived from a 129/Sv X 129/Sv-CP F1 3.5-day blastocysts from the Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada, were electroporated with 25 µg of linearized targeting construct and selected in both G418 (26 µmol/L) and gancyclovir (0.2 µmol/L). Genomic DNA from resistant clones was digested with Xhol, and analyzed by Southern blot hybridization with the 1.7-kb BamHI/Xhol genomic fragment (probe a in Figure 1A ). In a second step embryonic stem cell clones that had undergone homologous recombination were transfected with 25 µg of Cre-recombinase-expressing plasmid and selected for G418. Clones in which both the neo-cassette and exon 1 were deleted were identified by Southern blot analysis and PCR and injected into C57BL/6 blastocysts. PCR was performed using oligonucleotides directed against the 5' UTR [primer 1 (5'-GCGTTGGGGGGTGGAGGGAACTGCC-3')] and intron 1 [primer 2 (5'-CTGGCTCCACGAA-GCCTGG)]. Male chimeric mice were bred to C57BL/6 females to obtained heterozygous {alpha}2-deficient mice. Heterozygous mice were intercrossed to obtain wild-type, heterozygous, and {alpha}2-deficient animals.

Morphological and Histological Analyses

Mice at ages 9 to 11 weeks were euthanized by CO2 asphyxiation. Tissues were fixed in 4% formaldehyde and paraffin-embedded. Sections (4-µm) were stained with Harris’ hematoxylin and eosin.

Whole mounts of the mammary gland were prepared from the no. 4 inguinal gland by spreading the fatpad onto a precleaned glass slide, air-drying for 10 minutes, and fixing in acetic acid:ethanol (1:3) for 1 hour at room temperature. The tissue was dehydrated in 70% ethanol and ductal structures were stained with carmine solution (0.2% carmine and 0.5% aluminum potassium sulfate). The gland was dehydrated through graded ethanol, defatted in acetone, clarified in toluene, and mounted.

Reverse Transcriptase (RT)-PCR Analysis

Total RNA from whole mammary glands was isolated by the guanidine isothiocyanate extraction technique. First-strand cDNA synthesis of total RNA was performed using an oligonucleotide primer complementary to bp 3141 to 3161 of the murine {alpha}2 cDNA. RT-PCR was performed with the same PCR primer and one complimentary to bp 2320 to 2341 using standard PCR protocol.

Immunoblot Analysis

Purified platelet protein preparations or mammary glands were lysed in sodium dodecyl sulfate sample buffer [10% (v/v) glycerol/62.5 mmol/L Tris (pH 6.8)/2% sodium dodecyl sulfate/2% 2-mercaptoethanol], subjected to sodium dodecyl sulfate/polyacrylamide gel electrophoresis, and electroblotted onto Immobilon P transfer membrane (Millipore, Bedford, MA). Immunoblots were incubated with the appropriate dilution of each primary antibody and secondary horseradish peroxidase-conjugated donkey/anti-rabbit IgG antibody (Amersham, Arlington Heights, IL). The enhanced chemiluminescence system (Amersham) was used for visualization. The polyclonal antiserum against a portion of the carboxy terminus of the murine {alpha}2 integrin has been previously described.12 The goat polyclonal antiserum against actin was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

Platelet Preparation, Adhesion, and Aggregation Assays

Murine platelets were purified from citrated whole blood and resuspended in Ca2+-free solution to a final concentration of 1 x 108 platelets per ml, as previously described.13 When fixation was required, an equal volume of 2% paraformaldehyde in platelet buffer was added to the platelet suspensions, and the mixture was incubated at 37°C for 1 hour. Platelets were quantitated on a Hemavet 850 (CDC Technologies, Inc., Oxford, CT) and showed <0.1% contamination with leukocytes or erythrocytes.

Static adhesion assays were performed as previously described.14 Platelets purified from wild-type, heterozygous, and {alpha}2-integrin-deficient animals were prepared as described above and aliquotted into flat-bottom cells of a 96-well plate coated with either type I collagen or bovine serum albumin. The platelets were allowed to adhere for 1 hour at 37°C. Nonadherent platelets were removed by washing and the remaining attached platelets quantitated, as described.14

Platelet adhesion to substrates prepared with 100 µg/ml of equine tendon collagen (Helena Laboratories, Beaumont, TX) was assessed in a parallel-plate flow chamber apparatus as previously described.15 Platelets (1 x 108/ml) were perfused through the chamber at a shear rate of 150 seconds-1 for 5 minutes. The surface area covered by adherent platelets at the end of each experiment was determined (Image Pro Plus software) and expressed as a percentage of wild-type platelet adhesion. All experiments were performed in duplicate on different days.

Platelet aggregation was performed in siliconized glass cuvettes at 37°C with constant stirring (1200 rpm) using a dual-channel aggregometer (Payton Scientific, Buffalo, NY) using washed murine platelets (2 x 108/ml). Aggregation was initiated by either the addition of 2.5 or 5 µg/ml of soluble equine tendon collagen (Helena Laboratories) or 0.5 U/ml of murine thrombin (Sigma Immunochemicals, St. Louis, MO).

Flow Cytometry

Suspensions of paraformaldehyde-fixed platelets were incubated with the appropriate monoclonal antibody, washed with phosphate-buffered saline containing 1% bovine serum albumin and 5 mmol/L ethylenediaminetetraacetic acid, and subsequently incubated with fluorescein isothiocyanate-labeled secondary antibody (Zymed Laboratories, Inc., South San Francisco, CA) for 30 minutes at room temperature. The platelets were again washed and analyzed using a FACScan flow cytometer (Becton Dickinson Immunocytometry Systems, Mountain View, CA). The following previously described antibodies to murine antigens were obtained from BD PharMingen (San Diego, CA): HM{alpha}2 (anti-CD49b, hamster IgG), MEC 13.3 (anti-CD31, rat IgG2a), and isotype-matched control (rat anti-IgG2a). NAD-1 (anti-CD41/61, mouse anti-IgG) and anti-glycoprotein VI (GPVI) were generated to murine GPIIbIIIa complex and murine GPVI, respectively, using standard hybridoma techniques.16

Cutaneous Wounds

{alpha}2-deficient and wild-type mice were anesthetized with ketamine, dorsal hair was removed, and a 100-mm2 full-thickness wound was created by excising the skin. The wounds were photographed on day 0 and on every third day until they were completely healed. The size of the wound was digitally quantitated using Scion Image software.

Results

Targeted Disruption of the {alpha}2 Integrin Gene in Embryonic Stem Cells

To generate {alpha}2-integrin-null animals, we used a Cre-loxP targeting approach. The targeting vector was designed to flank exon 1 of the {alpha}2-integrin gene by two loxP sites and to place the PGK-neomycin resistance gene cassette upstream of exon 1 and the PGK-thymidine kinase gene downstream in the first intron. Embryonic stem cell clones with a targeted allele were transiently transfected with a Cre-recombinase encoding plasmid. Clones with deletion of both exon 1 and the neo-cassette were injected into host 129/Svj blastocysts. Chimeric animals with germline transmission of the targeted allele were obtained. Heterozygous mice were intercrossed to obtain mice homozygous for the {alpha}2 mutation. Genotypic analysis confirmed that mice lacking exon 1 of the {alpha}2-integrin gene were obtained (Figure 1, B and C) .

{alpha}2-Deficient Mice Are Viable and Fertile

Mice deficient in the {alpha}2ß1 integrin are viable and fertile and develop normally. Matings of heterozygous progeny yielded 22% wild-type, 58% heterozygous, and 21% homozygous mutant animals, consistent with typical Mendelian inheritance with no excess lethality of homozygotes. {alpha}2-null females produced viable litters of the expected sizes and nursed their young.

To verify that {alpha}2-integrin gene disruption generated a null allele and that the {alpha}2-null mice were deficient in expression of the {alpha}2ß1 integrin, platelets purified from the blood of wild-type, heterozygous, and homozygous mutant animals were evaluated by flow cytometric analysis using a fluorescein isothiocyanate-conjugated anti-murine {alpha}2 (CD49b) integrin subunit antibody. As shown in Figure 2A , the {alpha}2ß1 integrin was highly expressed by platelets from wild-type animals, as expected. In contrast, there was no detectable expression of the {alpha}2ß1 integrin on the platelets of {alpha}2-deficient animals. Intermediate levels of the {alpha}2ß1 integrin were detected on the surface of platelets from heterozygous littermates. Expression of CD31 and CD41/61 ({alpha}IIbß3, GPIIb/IIIa, the most abundant integrin on platelets) (Figure 2A) and GPVI on {alpha}2-deficient platelets was comparable to that on the platelets of wild-type and heterozygous littermates.



View larger version (43K):
[in this window]
[in a new window]
 
Figure 2. Expression of the {alpha}2 integrin subunit protein and mRNA. A: Flow cytometric analysis to detect extracellular expression of the {alpha}2ß1 integrin, CD31, and CD41/61 was performed on purified platelets from wild-type, heterozygous, and {alpha}2-deficient mice using fluorescein isothiocyanate-conjugated monoclonal anti-CD49b, CD31, or CD41/61 antibodies or isotype control. B: Immunoblot analysis of purified protein lysates from platelets or mammary glands derived from wild-type, heterozygous, and {alpha}2-deficient animals was performed with polyclonal rabbit antiserum directed against the carboxy-terminal 20 amino acids of the murine {alpha}2 integrin cytoplasmic domain or against actin. C: RT-PCR was performed on total RNA isolated from the mammary gland of wild-type, heterozygous, and {alpha}2-deficient mice. mRNA from wild-type and heterozygous animals generated an 840-bp product.

 
Western blot analysis of platelet lysate was also performed with a polyclonal rabbit antiserum directed against the carboxy-terminal 20 amino acids of the murine {alpha}2-integrin cytoplasmic domain. Neither full-length nor truncated {alpha}2-integrin subunit protein was detected from platelets of {alpha}2-null animals (Figure 2B) . The {alpha}2-integrin subunit was detected at intermediate level from platelets of heterozygous littermates and at high level from the wild-type littermates.

Western blot analysis and RT-PCR of protein lysates and mRNA of virgin female mammary glands established that the {alpha}2 integrin subunit was also effectively deleted from epithelial tissues. As shown in Figure 2, B and C , the wild-type mammary gland expressed the {alpha}2-integrin subunit protein and mRNA, as expected from previous studies.17 In contrast, the {alpha}2-integrin subunit was not detected in protein lysates (Figure 2B) or total RNA (Figure 2C) from the {alpha}2-null mammary gland.

{alpha}2 Integrin Subunit-Deficient Mice Develop Normally

Analysis of in vitro models of pulmonary, mammary, gastrointestinal, and renal development suggested a role for the {alpha}2ß1 integrin in epithelial differentiation and branching morphogenesis.5-8,18 However, {alpha}2-deficient mice appear grossly normal, are fertile, and are able to nurse their young. Gross and histological evaluation of a number of organs including the heart, lung, gastrointestinal tract, liver, kidney, pancreas, and reproductive tract failed to detect differences between the wild-type, heterozygous, and {alpha}2-deficient animals. Although the organization of the lungs, gastrointestinal tract, kidney, and mammary gland was entirely normal by histological sections in the {alpha}2-null animals (Figure 3A , top), whole-mount preparations of virgin female mammary gland revealed marked differences in branching complexity. As shown in Figure 3A , middle and bottom panels, the branching was much more extensive throughout the gland as well as at the terminal ducts in the wild-type mammary gland than in the {alpha}2-null gland. The number of branch points per terminal duct was 4 ± 1.7 in the wild-type gland versus 1.6 ± 0.2 (P = 0.0008) in the {alpha}2-null mammary gland, as shown in Figure 3B . These findings support a role for the {alpha}2ß1 integrin in branching morphogenesis in vivo.



View larger version (59K):
[in this window]
[in a new window]
 
Figure 3. Branching morphogenesis of the mammary gland. A: Histological sections of mammary glands of wild-type (+/+) and {alpha}2-deficient (-/-) animals 8 to 12 weeks of age were evaluated (top). Whole-mount preparations of 8- to 10-week-old virgin wild-type (+/+) and {alpha}2-deficient (-/-) mammary glands were stained with carmine solution. Terminal ducts were photographed at x100 (middle) and x1000 (bottom). B: The number of branch points per terminal duct was quantitated morphologically. The mean and SEM are shown.

 
Effects of {alpha}2 Integrin Deficiency on Platelet Function

Many studies have suggested that the {alpha}2ß1 integrin is a critical mediator of platelet adhesion to collagen within the vessel wall after vascular injury. Tail vein bleeding times in wild-type, heterozygous, and {alpha}2-deficient mice were similar (data not shown). Platelets purified from wild-type animals adhered under static conditions to collagen substrates in a Mg2+-dependent manner, as expected for {alpha}2ß1 integrin-mediated adhesion (Figure 4A) . In contrast, platelets purified from {alpha}2-deficient mice failed to adhere to type I collagen. Platelets from heterozygous littermates exhibited intermediate adhesion. Platelets from all animals adhered to fibronectin in a comparable manner (data not shown), but failed to adhere to bovine serum albumin.



View larger version (41K):
[in this window]
[in a new window]
 
Figure 4. Platelet adhesion and aggregation. A: Platelets purified from wild-type (+/+), heterozygous (+/-), and {alpha}2-deficient (-/-) animals were assayed for adhesion to type I collagen. The assays were performed for 1 hour in phosphate-buffered saline with 2 mmol/L of Mg2+ or ethylenediaminetetraacetic acid. B: Platelet adhesion to type I collagen at shear rates of 150 seconds-1 was assayed in a parallel-plate flow chamber apparatus. Micrographs of the collagen substrate and the deposition of platelets from wild-type (+/+), heterozygous (+/-), and {alpha}2-deficient (-/-) mice are depicted. C: The surface area covered by adherent wild-type, heterozygous, or {alpha}2-deficient platelets was quantitated and expressed as a percentage of wild-type platelet adhesion. D: Platelet aggregation of heterozygous (+/-) or {alpha}2-deficient (-/-) platelets was initiated by either the addition of 2.5 or 5 µg/ml of soluble equine tendon collagen or 0.5 U/ml of thrombin.

 
As shown in Figure 4, B and C , purified platelets from wild-type mice also effectively adhered to type I collagen at shear rates of 150 seconds-1, a flow rate in which exogenous Von Willebrand factor is not required. In contrast, platelets from {alpha}2-deficient mice failed to adhere under shear stress. Platelets from heterozygous mice again adhered to an intermediate extent, indicative of a gene dosage effect and suggesting that there are few, if any, spare {alpha}2ß1 collagen receptors. As also shown in Figure 4B , platelets from both wild-type and heterozygous mice formed small platelet thrombi on the collagen substrates under conditions of flow.

Platelets from wild-type and heterozygous animals comparably aggregated in response to low concentrations of collagen (2.5 and 5 µg/ml) (Figure 4D) . Although platelets from {alpha}2-null animals aggregated in response to type I collagen, they did so with a significantly prolonged lag phase and a decreased rate of aggregation.

{alpha}2ß1 Integrin and Wound Healing

The {alpha}2ß1 integrin is highly expressed by the basal cell layer of the skin and moderately expressed by dermal fibroblasts. In vitro and explant studies of matrix contraction and wound healing suggested that the {alpha}2ß1 integrin may serve a role in the normal organization of the dermis and an obligatory role in wound healing.9,10 Histological evaluation of full-thickness skin biopsies of wild-type and {alpha}2-null animals identified no detectable differences (Figure 5A) . In both cases the epidermis was composed of layers of stratified squamous epithelium attached to the basal cell layer. The dermis in the {alpha}2-null and wild-type animals contained comparable numbers of fibroblasts and well-organized collagen bundles.



View larger version (66K):
[in this window]
[in a new window]
 
Figure 5. {alpha}2ß1 integrin and wound healing. A: Photomicrographs of full-thickness skin biopsies from wild-type or {alpha}2-null mice revealed no differences in skin development. The dermis of both animals contained comparable numbers of fibroblasts and organized collagen bundles. B: The size of a 100-mm full-thickness wound was digitally quantitated from day 0 to day 18, when all wounds were healed. Both wild-type and {alpha}2-null animals exhibit similar rates of wound healing.

 
To determine whether the {alpha}2ß1 integrin was required for wound healing, the ability to close a 100-mm2 full-thickness wound was evaluated. Compared to wild-type animals, {alpha}2-deficient mice demonstrated no defect in wound repair and all animals displayed a similar temporal pattern of wound healing (Figure 5B) . In fact, wound healing on day 12 was slightly enhanced in the {alpha}2-null animals compared to wild-type littermates. The morphology of the wounds failed to demonstrate any difference in keratinocyte migration or angiogenesis into the wound site (data not shown).

Discussion

The expression of the {alpha}2ß1 integrin by diverse cell types raised many questions regarding the role of the {alpha}2ß1 integrin in vivo. Indeed, the {alpha}2ß1-integrin-null mouse exhibits a multifaceted phenotype. In some cases, such as platelets and mammary epithelial cells, the null phenotype was consistent with predictions based on the expression pattern of the integrin and consistent with the in vitro data. In other instances, the in vivo findings suggest alternative mechanisms for biological processes such as wound healing, and reject the proposed obligatory role for the {alpha}2ß1 integrin.

Although the {alpha}2ß1 integrin is expressed at high level in the placenta and in many other tissues during embryogenesis,12 its expression is not required for normal murine development. Deficiency of the {alpha}2ß1 integrin had no effect on offspring viability or fertility of the {alpha}2-deficient animals.

The {alpha}2ß1 integrin is highly expressed at sites of terminal duct branching in the developing mammary gland and lung.12,17 The significant decrement in branching complexity observed in the mammary glands of {alpha}2ß1 integrin-deficient animals supports an important role for the integrin in branching morphogenesis in vivo.5-8 The results of the in vivo studies, although striking, were less dramatic than the complete absence of branching morphogenesis observed in the absence or inhibition of the {alpha}2ß1 integrin in earlier in vitro studies in three-dimensional collagen gels. The in vitro models were designed to study a single integrin interaction with a single matrix molecule. Mammary epithelial cells express a wide variety of integrin and nonintegrin adhesion receptors that interact with multiple components of the extracellular matrix in vivo and may mitigate the consequences of {alpha}2ß1 integrin deficiency.

The mechanism by which branching is impaired in the {alpha}2-deficient mouse is not yet understood. One possibility is defective proliferation of {alpha}2ß1-integrin-deficient mammary epithelial cells. Recent studies have established that the integrin is an important determinant of growth factor-dependent cell cycle progression of mammary epithelial cells.18,19 Whether the differences seen at weeks 9 to 11 are because of defective branching per se, or rather to a delay in development, is uncertain. Future studies will evaluate the mammary gland during all stages of maturation including puberty, gestation, and involution. However, the {alpha}2-deficient mammary gland is capable of lactation and the {alpha}2-deficient animals can adequately nurse their young despite the deficit in branching complexity. Litters of {alpha}2-deficient females do not show a growth defect. Our earlier studies established a strong correlation between diminished {alpha}2ß1 integrin expression and a less differentiated phenotype in breast cancer.20,21 The {alpha}2ß1-integrin-deficient mouse should afford a system to further assess the relationship between {alpha}2ß1 integrin expression and the development and phenotype of breast carcinomas.

The lack of obvious abnormalities in other organs such as the lung, gastrointestinal tract, and kidney may be because of the subtlety of lesions in these organs not detected by standard histopathological evaluation. In the mammary gland, the differences were most obvious in whole-mount preparations, but not readily apparent in cross sections of the mammary gland. More detailed examinations of other organs are required to exclude this possibility.

In vitro studies of human skin have suggested that the {alpha}2ß1 integrin is required for wound healing.9-10 Inhibitory antibodies against the {alpha}2ß1 integrin prevent keratinocyte migration on type I collagen and across wounded dermis and block fibroblast contraction of three-dimensional collagen gels.9-10 However, deficiency of the {alpha}2ß1 integrin failed to alter wound healing in vivo and had no effect on the migration of keratinocytes over exposed dermis (data not shown) suggesting that {alpha}2ß1 integrin does not play an obligatory role in wound healing. There are at least two possible explanations for the discrepancy. One arises from the use of two different organisms that may not be mechanistically equivalent as model systems. Second, on binding the integrin, inhibitory antibodies may stimulate signals downstream of the integrin that are responsible for the observed phenotype. Thus, antibodies could produce effects that differ from those because of lack of integrin expression.

The profound deficit in platelet adhesion to collagen observed with platelets from {alpha}2 integrin subunit-deficient animals is in accord with earlier studies addressing the role of the {alpha}2ß1 integrin as a collagen receptor on platelets by less direct approaches.4 The lack of {alpha}2ß1 integrin expression did not effect the expression of the other major platelet integrin, {alpha}IIbß3 (CD41/61). The magnitude of the deficit under both static conditions and conditions of flow clearly indicates that the {alpha}2ß1 integrin is the dominant adhesive receptor for collagen on platelets.

Other putative receptors are unable to support significant adhesion in the absence of the {alpha}2ß1 integrin not only under conditions of flow, but also under the less rigorous static conditions. The dramatic reduction in adhesion of heterozygous platelets under both static and flow conditions is consistent with a gene dosage effect and suggests that the level of {alpha}2ß1 integrin expression profoundly influences the adhesive functions of platelets on collagenous substrates. This provides an animal model to evaluate the molecular mechanisms by which allelic differences in the {alpha}2 integrin gene and different levels of {alpha}2ß1 integrin expression are associated with increased risk of myocardial infarction, diabetic retinopathy, and stroke.22-25 The adhesive decrement in heterozygotes suggests that the receptor is not present in significant excess.

The results of the platelet studies are primarily consistent with the two-step, two-site model of collagen-induced platelet activation.26 In this model, adhesion is mediated by the {alpha}2ß1 integrin, whereas collagen-induced activation and aggregation is mediated by a second, low-affinity signal-transducing co-receptor. Recent studies suggest that GPVI serves the role of the signal-transducing co-receptor. Under the extremely low shear conditions of the aggregation assay, as opposed to the more stringent conditions of the adhesion assays, our data suggest that GPVI is sufficient to support activation and aggregation although at a somewhat reduced level. Collagen is only one of several physiologically relevant activators of platelets. The presence of other potent activators, such as thrombin, at the sites of vascular injury in vivo, likely accounts for the relatively normal tail vein bleeding times observed and the absence of an overt bleeding diathesis.

Some comparison with the recently published study of collagen-induced platelet aggregation and adhesion in platelets deficient in the ß1 integrin subunit is warranted.27 The findings regarding collagen-induced platelet aggregation and adhesion to substrates of monomeric collagen are primarily in accord. The studies of adhesion to fibrillar substrates described by Nieswandt and colleagues27 were likely confounded by the highly thrombogenic nature of fibrillar collagen substrates and the relatively intact aggregation response to collagen exhibited by platelets deficient in the {alpha}2ß1 integrin. It should also be noted that differences between {alpha}2ß1-deficient and control platelets were minimized by reconstituting washed platelets in media containing 1 mmol/L of Ca++ thereby suppressing {alpha}2ß1 integrin functions. The model presented above, but not that of Nieswandt and colleagues,27 is also consistent with the findings of studies with human platelets deficient in GPVI. GPVI-deficient platelets exhibit markedly impaired collagen-induced aggregation and activation, little or no defect in adhesion per se, and a modest decrement in total platelet deposition (adhesion plus aggregation) on collagen substrates measured under conditions of flow that was attributable to the loss of platelet-platelet interactions.28,29

In addition to profoundly deficient adhesion to collagen, the platelets deficient in the {alpha}2ß1 integrin of a patient described by Nieuwenhuis and colleagues30,31 also exhibited markedly impaired (essentially undetectable) collagen-induced platelet aggregation. This finding is at variance with both our study of the {alpha}2-integrin subunit null mouse and the study of Nieswandt and colleagues27 of the ß1-integrin subunit-deficient mouse. It seems likely that the platelets of the patient described by Nieuwenhuis and colleagues30,31 exhibit an additional defect resulting in the absence of collagen-induced platelet aggregation. Alternately, the relative contributions of the {alpha}2ß1 integrin, glycoprotein VI, and perhaps other receptors and signaling pathways differ in human and murine platelets.

Acknowledgements

We thank Bruce Linders and George Li for expert technical assistance and Mary Beth Flynn for excellent secretarial assistance.

Footnotes

Address reprint requests to Mary M. Zutter, Washington University School of Medicine, Department of Pathology & Immunology, 660 S. Euclid Ave., Campus Box 8118, St. Louis, MO 63110. E-mail: zutter{at}path.wustl.edu

Supported by the National Institutes of Health (grants CA70275, CA83690, and HL63446).

Accepted for publication April 5, 2002.

References

  1. Staatz WD, Rajpara SM, Wayner EA, Carter WG, Santoro SA: The membrane glycoprotein Ia-IIa (VLA-2) complex mediates the Mg++-dependent adhesion of platelets to collagen. J Cell Biol 1989, 108:1917-1924[Abstract/Free Full Text]
  2. Elices MJ, Hemler ME: The human integrin VLA-2 is a collagen receptor on some cells and a collagen/laminin receptor on others. Proc Natl Acad Sci USA 1989, 86:9906-9910[Abstract/Free Full Text]
  3. Kirchhofer D, Languino LR, Ruoslahti E, Pierschbacher MD: Alpha 2 beta 1 integrins from different cell types show different binding specificities. J Biol Chem 1990, 265:615-618[Abstract/Free Full Text]
  4. Santoro SA, Zutter MM: The alpha 2 beta 1 integrin: a collagen receptor on platelets and other cells. Thromb Haemost 1995, 74:813-821[Medline]
  5. Berdichevsky F, Alford D, D’Souza B, Taylor-Papadimitriou J: Branching morphogenesis of human mammary epithelial cells in collagen gels. J Cell Sci 1994, 107:3557-3568[Abstract]
  6. Saelman EU, Keely PJ, Santoro SA: Loss of MDCK cell alpha 2 beta 1 integrin expression results in reduced cyst formation, failure of hepatocyte growth factor/scatter factor-induced branching morphogenesis, and increased apoptosis. J Cell Sci 1995, 108:3531-3540[Abstract]
  7. Zutter MM, Santoro SA, Staatz WD, Tsung YL: Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc Natl Acad Sci USA 1995, 92:7411-7415[Abstract/Free Full Text]
  8. Zutter MM, Sun H, Santoro SA: Altered integrin expression and the malignant phenotype: the contribution of multiple integrated integrin receptors. J Mammary Gland Biol Neoplasia 1998, 3:191-200[Medline]
  9. Xu J, Clark RA: A three-dimensional collagen lattice induces protein kinase C-zeta activity: role in alpha2 integrin and collagenase mRNA expression. J Cell Biol 1997, 136:473-483[Abstract/Free Full Text]
  10. Pilcher BK, Dumin JA, Sudbeck BD, Krane SM, Welgus HG, Parks WC: The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. J Cell Biol 1997, 137:1445-1457[Abstract/Free Full Text]
  11. Dumin JA, Dickeson SK, Stricker TP, Bhattacharyya-Pakrasi M, Roby JD, Santoro SA, Parks WC: Pro-collagenase-1 (matrix metalloproteinase-1) binds the alpha(2)beta(1) integrin upon release from keratinocytes migrating on type I collagen. J Biol Chem 2001, 276:29368-29374[Abstract/Free Full Text]
  12. Wu JE, Santoro SA: Complex patterns of expression suggest extensive roles for the alpha 2 beta 1 integrin in murine development. Dev Dyn 1994, 199:292-314[Medline]
  13. Kahn ML, Diacovo TG, Bainton DF, Lanza F, Trejo J, Coughlin SR: Glycoprotein V-deficient platelets have undiminished thrombin responsiveness and do not exhibit a Bernard-Soulier phenotype. Blood 1999, 94:4112-4121[Abstract/Free Full Text]
  14. Santoro SA, Zutter MM, Wu JE, Staatz WD, Saelman EU, Keely PJ: Analysis of collagen receptors. Methods Enzymol 1994, 245:147-183[Medline]
  15. Cruz MA, Diacovo TG, Emsley J, Liddington R, Handin RI: Mapping the glycoprotein Ib-binding site in the von Willebrand factor A1 domain. J Biol Chem 2000, 275:19098-19105[Abstract/Free Full Text]
  16. Langone JJ, Van Vunakis H: Immunohistochemical Techniques. Langone JJ Van Vunakis H eds. Part I: Hybridoma Technology and Monoclonal Antibodies. 1986:pp 1-947 Academic Press, San Diego, CA
  17. Keely PJ, Wu JE, Santoro SA: The spatial and temporal expression of the alpha 2 beta 1 integrin and its ligands, collagen I, collagen IV, and laminin, suggest important roles in mouse mammary morphogenesis. Differentiation 1995, 59:1-13[Medline]
  18. Klekotka PA, Santoro SA, Zutter MM: Alpha 2 integrin subunit cytoplasmic domain-dependent cellular migration requires p38 MAPK. J Biol Chem 2001, 276:9503-9511[Abstract/Free Full Text]
  19. Klekotka PA, Santoro SA, Ho A, Dowdy SF, Zutter MM: Mammary epithelial cell-cycle progression via the alpha(2)beta(1) integrin: unique and synergistic roles of the alpha(2) cytoplasmic domain. Am J Pathol 2001, 159:983-992[Abstract/Free Full Text]
  20. Zutter MM, Mazoujian G, Santoro SA: Decreased expression of integrin adhesive protein receptors in adenocarcinoma of the breast. Am J Pathol 1990, 137:863-870[Abstract]
  21. Zutter MM, Santoro SA: The ups and downs of alpha 2 beta 1-integrin expression: contributions to epithelial cell differentiation and the malignant phenotype. Curr Top Microbiol Immunol 1998, 231:167-185[Medline]
  22. Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ: Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. Blood 1998, 92:2382-2388[Abstract/Free Full Text]
  23. Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A: Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 1999, 93:2449-2453[Abstract/Free Full Text]
  24. Matsubara Y, Murata M, Maruyama T, Handa M, Yamagata N, Watanabe G, Saruta T, Ikeda Y: Association between diabetic retinopathy and genetic variations in alpha2beta1 integrin, a platelet receptor for collagen. Blood 2000, 95:1560-1564[Abstract/Free Full Text]
  25. Carlsson LE, Santoso S, Spitzer C, Kessler C, Greinacher A: The alpha2 gene coding sequence T807/A873 of the platelet collagen receptor integrin alpha2beta1 might be a genetic risk factor for the development of stroke in younger patients. Blood 1999, 93:3583-3586[Abstract/Free Full Text]
  26. Santoro SA, Walsh JJ, Staatz WD, Baranski KJ: Distinct determinants on collagen support alpha 2 beta 1 integrin-mediated platelet adhesion and platelet activation. Cell Regul 1991, 2:905-913[Medline]
  27. Nieswandt B, Brakebusch C, Bergmeier W, Schulte V, Bouvard D, Mokhtari-Nejad R, Lindhout T, Heemskerk JW, Zirngibl H, Fassler R: Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J 2001, 20:2120-2130[Medline]
  28. Kehrel B, Wierwille S, Clemetson KJ, Anders O, Steiner M, Knight CG, Farndale RW, Okuma M, Barnes MJ: Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa and von Willebrand factor do not. Blood 1998, 91:491-499[Abstract/Free Full Text]
  29. Ichinoke T, Takayama H, Ezumi Y, Arai M, Yamamoto N, Takahashi H, Okuma M: Collagen-stimulated activation of syk but not c-src is severely compromised in human platelets lacking membrane glycoprotein VI. J Biol Chem 1997, 272:63-68[Abstract/Free Full Text]
  30. Nieuwenhuis HK, Akkerman JW, Houdijk WP, Sixma JJ: Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature 1985, 318:470-472[Medline]
  31. Nieuwenhuis HK, Sakariassen KS, Houdijk WP, Nievelstein PF, Sixma JJ: Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood 1986, 68:692-695[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
M. Jafri, B. Donnelly, S. Allen, A. Bondoc, M. McNeal, P. D. Rennert, P. H. Weinreb, R. Ward, and G. Tiao
Cholangiocyte expression of {alpha}2{beta}1-integrin confers susceptibility to rotavirus-induced experimental biliary atresia
Am J Physiol Gastrointest Liver Physiol, July 1, 2008; 295(1): G16 - G26.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Biol.Home page
N. Watanabe, L. Bodin, M. Pandey, M. Krause, S. Coughlin, V. A. Boussiotis, M. H. Ginsberg, and S. J. Shattil
Mechanisms and consequences of agonist-induced talin recruitment to platelet integrin {alpha}IIb{beta}3
J. Cell Biol., June 30, 2008; 181(7): 1211 - 1222.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
D. Varga-Szabo, I. Pleines, and B. Nieswandt
Cell Adhesion Mechanisms in Platelets
Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): 403 - 412.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Z. Zhang, N. E. Ramirez, T. E. Yankeelov, Z. Li, L. E. Ford, Y. Qi, A. Pozzi, and M. M. Zutter
{alpha}2{beta}1 integrin expression in the tumor microenvironment enhances tumor angiogenesis in a tumor cell-specific manner
Blood, February 15, 2008; 111(4): 1980 - 1988.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
B. G. Petrich, P. Marchese, Z. M. Ruggeri, S. Spiess, R. A.M. Weichert, F. Ye, R. Tiedt, R. C. Skoda, S. J. Monkley, D. R. Critchley, et al.
Talin is required for integrin-mediated platelet function in hemostasis and thrombosis
J. Exp. Med., December 24, 2007; 204(13): 3103 - 3111.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
S. N. Popova, M. Barczyk, C.-F. Tiger, W. Beertsen, P. Zigrino, A. Aszodi, N. Miosge, E. Forsberg, and D. Gullberg
{alpha}11{beta}1 Integrin-Dependent Regulation of Periodontal Ligament Function in the Erupting Mouse Incisor
Mol. Cell. Biol., June 15, 2007; 27(12): 4306 - 4316.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
U. J.H. Sachs and B. Nieswandt
In Vivo Thrombus Formation in Murine Models
Circ. Res., April 13, 2007; 100(7): 979 - 991.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. V. Denis and D. D. Wagner
Platelet Adhesion Receptors and Their Ligands in Mouse Models of Thrombosis
Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 728 - 739.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. J. del Zoppo and R. Milner
Integrin-Matrix Interactions in the Cerebral Microvasculature
Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 1966 - 1975.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
Z.-G. Zhang, I. Bothe, F. Hirche, M. Zweers, D. Gullberg, G. Pfitzer, T. Krieg, B. Eckes, and M. Aumailley
Interactions of primary fibroblasts and keratinocytes with extracellular matrix proteins: contribution of {alpha}2{beta}1 integrin.
J. Cell Sci., May 1, 2006; 119(Pt 9): 1886 - 1895.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
A. Pajoohesh-Ganji, S. Pal-Ghosh, S. J. Simmens, and M. A. Stepp
Integrins in Slow-Cycling Corneal Epithelial Cells at the Limbus in the Mouse
Stem Cells, April 1, 2006; 24(4): 1075 - 1086.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
A. J. Wagers and I. L. Weissman
Differential Expression of {alpha}2 Integrin Separates Long-Term and Short-Term Reconstituting Lin-/loThy1.1loc-kit+ Sca-1+ Hematopoietic Stem Cells
Stem Cells, April 1, 2006; 24(4): 1087 - 1094.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. T. Edelson, T. P. Stricker, Z. Li, S. K. Dickeson, V. L. Shepherd, S. A. Santoro, and M. M. Zutter
Novel collectin/C1q receptor mediates mast cell activation and innate immunity
Blood, January 1, 2006; 107(1): 143 - 150.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. L. Sarratt, H. Chen, M. M. Zutter, S. A. Santoro, D. A. Hammer, and M. L. Kahn
GPVI and {alpha}2{beta}1 play independent critical roles during platelet adhesion and aggregate formation to collagen under flow
Blood, August 15, 2005; 106(4): 1268 - 1277.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
R. Montesano, P. Soulie, J. A. Eble, and F. Carrozzino
Tumour necrosis factor {alpha} confers an invasive, transformed phenotype on mammary epithelial cells
J. Cell Sci., August 1, 2005; 118(15): 3487 - 3500.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Kapyla, J. Jaalinoja, M. Tulla, J. Ylostalo, L. Nissinen, T. Viitasalo, P. Vehvilainen, V. Marjomaki, P. Nykvist, A.-M. Saamanen, et al.
The Fibril-associated Collagen IX Provides a Novel Mechanism for Cell Adhesion to Cartilaginous Matrix
J. Biol. Chem., December 3, 2004; 279(49): 51677 - 51687.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. R.-M. Siljander, S. Hamaia, A. R. Peachey, D. A. Slatter, P. A. Smethurst, W. H. Ouwehand, C. G. Knight, and R. W. Farndale
Integrin Activation State Determines Selectivity for Novel Recognition Sites in Fibrillar Collagens
J. Biol. Chem., November 12, 2004; 279(46): 47763 - 47772.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Gruner, M. Prostredna, B. Aktas, A. Moers, V. Schulte, T. Krieg, S. Offermanns, B. Eckes, and B. Nieswandt
Anti-Glycoprotein VI Treatment Severely Compromises Hemostasis in Mice With Reduced {alpha}2{beta}1 Levels or Concomitant Aspirin Therapy
Circulation, November 2, 2004; 110(18): 2946 - 2951.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
F. F. Samaha, C. Hibbard, J. Sacks, H. Chen, M. A. Varello, T. George, and M. L. Kahn
Measurement of Platelet Collagen Receptor Density in Human Subjects
Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): e181 - e182.
[Full Text] [PDF]


Home page
BloodHome page
T. J. Kunicki, A. B. Federici, D. R. Salomon, J. A. Koziol, S. R. Head, T. S. Mondala, J. D. Chismar, L. Baronciani, M. T. Canciani, and I. R. Peake
An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees
Blood, October 15, 2004; 104(8): 2359 - 2367.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
D. Chen, R. Roberts, M. Pohl, S. Nigam, J. Kreidberg, Z. Wang, J. Heino, J. Ivaska, S. Coffa, R. C. Harris, et al.
Differential expression of collagen- and laminin-binding integrins mediates ureteric bud and inner medullary collecting duct cell tubulogenesis
Am J Physiol Renal Physiol, October 1, 2004; 287(4): F602 - F611.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
J. M. Gibbins
Platelet adhesion signalling and the regulation of thrombus formation
J. Cell Sci., July 15, 2004; 117(16): 3415 - 3425.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T.-T. Li, S. Larrucea, S. Souza, S. M. Leal, J. A. Lopez, E. M. Rubin, B. Nieswandt, and P. F. Bray
Genetic variation responsible for mouse strain differences in integrin {alpha}2 expression is associated with altered platelet responses to collagen
Blood, May 1, 2004; 103(9): 3396 - 3402.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
M. A. Sanders and M. D. Basson
Collagen IV regulates Caco-2 migration and ERK activation via {alpha}1{beta}1- and {alpha}2{beta}1-integrin-dependent Src kinase activation
Am J Physiol Gastrointest Liver Physiol, April 1, 2004; 286(4): G547 - G557.
[Abstract] [Full Text] [PDF]